View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsMerrimack Pharmaceuticals 배당 및 자사주 매입배당 기준 점검 0/6Merrimack Pharmaceuticals 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-0.8%자사주 매입 수익률총 주주 수익률-0.8%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트공시 • May 11Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Payable on or About May 17, 2024Merrimack Pharmaceuticals, Inc. announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of Dissolution is obtained at the Special Meeting of Stockholders held on May 10, 2024. The dividend is expected to be paid on or about May 17, 2024, to stockholders of record on May 10, 2024.모든 업데이트 보기Recent updates공시 • May 21Merrimack Pharmaceuticals Files Form 15Merrimack Pharmaceuticals, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.01 per share.공시 • May 11Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Payable on or About May 17, 2024Merrimack Pharmaceuticals, Inc. announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of Dissolution is obtained at the Special Meeting of Stockholders held on May 10, 2024. The dividend is expected to be paid on or about May 17, 2024, to stockholders of record on May 10, 2024.공시 • May 01Merrimack Pharmaceuticals Intends to Voluntary Delist Class A Common StockPursuant to the Plan of Dissolution, on April 30, 2024, Merrimack Pharmaceuticals, Inc. notified The Nasdaq Stock Market LLC (Nasdaq") of its intention to voluntarily delist its shares of Class A common stock, par value $0.01 per share (the Common Stock") from Nasdaq and deregister the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act"). The Company currently estimates a cash dividend for the initial liquidating distribution in the range of $14.92 to $15.15 per share. Such range is an estimate and the actual cash dividend amount, which is expected to be announced on or about May 8, 2024, may fall outside of this range and is subject To Approve the Plan of Dissolution by stockholders at the Special Meeting. The Company intends to file with the SEC a Form 25 on or about May 10, 2024 to effect the delisting and deregistration of the Common Stock from Nasdaq under Section 12(b) of the Exchange Act, if the proposed liquidation and dissolution of the Company is approved by stockholders at the Special Meeting. The delisting will become effective later in May. Upon the effectiveness of the Form 25, the Company also intends to file a Form 15 with the SEC on or about May 20, 2024 to suspend the Company's reporting obligations under Sections 13 and 15(d) of the Exchange Act and deregister the Common Stock under Section 12(b) of the Exchange Act.분석 기사 • Feb 14We're Not Worried About Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash BurnJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...공시 • Nov 10Merrimack Pharmaceuticals, Inc. Provides Ipsen Report That Onivyde Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal AdenocarcinomaMerrimack Pharmaceuticals, Inc. announced that Ipsen, SA issued a press release reporting its primary analysis of the results of its Phase III NAPOLI 3 trial of Onivyde (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) as a treatment of first line metastatic pancreatic ductal adenocarcinoma (mPDAC). The Ipsen press release indicates that the trial “met its primary endpoint demonstrating clinically meaningful and statistically significant improvement in overall survival compared to nab-paclitaxel plus gemcitabine in 770 previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and key secondary efficacy outcome of progression-free survival also showed significant improvement over the comparator arm. The safety profile of Onivyde in the NAPOLI 3 trial was consistent with those observed in the previous phase I/II mPDAC study.” Ipsen indicated in its update that it intends to file a supplemental New Drug Application with the U.S. Food and Drug Administration for Onivyde in combination with oxaliplatin plus 5- fluorouracil/leucovorin for the treatment of patients with previously untreated mPDAC following the Fast Track Designation granted in 2020.분석 기사 • Sep 23Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Aug 04Merrimack Pharmaceuticals GAAP EPS of -$0.04Merrimack Pharmaceuticals press release (NASDAQ:MACK): Q2 GAAP EPS of -$0.04. As of June 30, 2022, Merrimack had cash and cash equivalents of $13.4 million, compared to $14.2 million as of December 31, 2021.Recent Insider Transactions • Mar 22President recently bought US$61k worth of stockOn the 14th of March, Gary Crocker bought around 10k shares on-market at roughly US$6.05 per share. In the last 3 months, they made an even bigger purchase worth US$80k. Gary has been a buyer over the last 12 months, purchasing a net total of US$439k worth in shares.분석 기사 • Mar 19Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Recent Insider Transactions • Feb 22President recently bought US$80k worth of stockOn the 17th of February, Gary Crocker bought around 13k shares on-market at roughly US$6.17 per share. This was the largest purchase by an insider in the last 3 months. Gary has been a buyer over the last 12 months, purchasing a net total of US$399k worth in shares.Recent Insider Transactions • Jan 27Co-Founder & Independent Director recently bought US$61k worth of stockOn the 24th of January, Ulrik Nielsen bought around 14k shares on-market at roughly US$4.24 per share. This was the largest purchase by an insider in the last 3 months. This was Ulrik's only on-market trade for the last 12 months.분석 기사 • May 19We're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To GrowEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Recent Insider Transactions • Mar 27President recently bought US$55k worth of stockOn the 24th of March, Gary Crocker bought around 9k shares on-market at roughly US$6.39 per share. This was the largest purchase by an insider in the last 3 months. Gary has been a buyer over the last 12 months, purchasing a net total of US$202k worth in shares.Is New 90 Day High Low • Mar 05New 90-day low: US$6.44The company is down 9.0% from its price of US$7.07 on 04 December 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.분석 기사 • Feb 22Are Insiders Selling Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Stock?We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...Is New 90 Day High Low • Feb 11New 90-day high: US$8.70The company is up 135% from its price of US$3.71 on 12 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period.분석 기사 • Jan 01Merrimack Pharmaceuticals (NASDAQ:MACK) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, Merrimack...Is New 90 Day High Low • Nov 13New 90-day low: US$3.71The company is down 14% from its price of US$4.30 on 14 August 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period.공시 • Jul 04Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from Russell Microcap Value IndexMerrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from Russell Microcap Value Index지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 MACK 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: MACK 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Merrimack Pharmaceuticals 배당 수익률 vs 시장MACK의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (MACK)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.4%분석가 예측 (MACK) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 MACK 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 MACK 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 MACK 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: MACK 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/05/21 23:19종가2024/05/17 00:00수익2024/03/31연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Merrimack Pharmaceuticals, Inc.는 8명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Michael UlzBairdRachel McMinnBofA Global ResearchDaniel BrimsCantor Fitzgerald & Co.5명의 분석가 더 보기
공시 • May 11Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Payable on or About May 17, 2024Merrimack Pharmaceuticals, Inc. announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of Dissolution is obtained at the Special Meeting of Stockholders held on May 10, 2024. The dividend is expected to be paid on or about May 17, 2024, to stockholders of record on May 10, 2024.
공시 • May 21Merrimack Pharmaceuticals Files Form 15Merrimack Pharmaceuticals, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.01 per share.
공시 • May 11Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Payable on or About May 17, 2024Merrimack Pharmaceuticals, Inc. announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of Dissolution is obtained at the Special Meeting of Stockholders held on May 10, 2024. The dividend is expected to be paid on or about May 17, 2024, to stockholders of record on May 10, 2024.
공시 • May 01Merrimack Pharmaceuticals Intends to Voluntary Delist Class A Common StockPursuant to the Plan of Dissolution, on April 30, 2024, Merrimack Pharmaceuticals, Inc. notified The Nasdaq Stock Market LLC (Nasdaq") of its intention to voluntarily delist its shares of Class A common stock, par value $0.01 per share (the Common Stock") from Nasdaq and deregister the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act"). The Company currently estimates a cash dividend for the initial liquidating distribution in the range of $14.92 to $15.15 per share. Such range is an estimate and the actual cash dividend amount, which is expected to be announced on or about May 8, 2024, may fall outside of this range and is subject To Approve the Plan of Dissolution by stockholders at the Special Meeting. The Company intends to file with the SEC a Form 25 on or about May 10, 2024 to effect the delisting and deregistration of the Common Stock from Nasdaq under Section 12(b) of the Exchange Act, if the proposed liquidation and dissolution of the Company is approved by stockholders at the Special Meeting. The delisting will become effective later in May. Upon the effectiveness of the Form 25, the Company also intends to file a Form 15 with the SEC on or about May 20, 2024 to suspend the Company's reporting obligations under Sections 13 and 15(d) of the Exchange Act and deregister the Common Stock under Section 12(b) of the Exchange Act.
분석 기사 • Feb 14We're Not Worried About Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash BurnJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
공시 • Nov 10Merrimack Pharmaceuticals, Inc. Provides Ipsen Report That Onivyde Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal AdenocarcinomaMerrimack Pharmaceuticals, Inc. announced that Ipsen, SA issued a press release reporting its primary analysis of the results of its Phase III NAPOLI 3 trial of Onivyde (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) as a treatment of first line metastatic pancreatic ductal adenocarcinoma (mPDAC). The Ipsen press release indicates that the trial “met its primary endpoint demonstrating clinically meaningful and statistically significant improvement in overall survival compared to nab-paclitaxel plus gemcitabine in 770 previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and key secondary efficacy outcome of progression-free survival also showed significant improvement over the comparator arm. The safety profile of Onivyde in the NAPOLI 3 trial was consistent with those observed in the previous phase I/II mPDAC study.” Ipsen indicated in its update that it intends to file a supplemental New Drug Application with the U.S. Food and Drug Administration for Onivyde in combination with oxaliplatin plus 5- fluorouracil/leucovorin for the treatment of patients with previously untreated mPDAC following the Fast Track Designation granted in 2020.
분석 기사 • Sep 23Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 04Merrimack Pharmaceuticals GAAP EPS of -$0.04Merrimack Pharmaceuticals press release (NASDAQ:MACK): Q2 GAAP EPS of -$0.04. As of June 30, 2022, Merrimack had cash and cash equivalents of $13.4 million, compared to $14.2 million as of December 31, 2021.
Recent Insider Transactions • Mar 22President recently bought US$61k worth of stockOn the 14th of March, Gary Crocker bought around 10k shares on-market at roughly US$6.05 per share. In the last 3 months, they made an even bigger purchase worth US$80k. Gary has been a buyer over the last 12 months, purchasing a net total of US$439k worth in shares.
분석 기사 • Mar 19Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Recent Insider Transactions • Feb 22President recently bought US$80k worth of stockOn the 17th of February, Gary Crocker bought around 13k shares on-market at roughly US$6.17 per share. This was the largest purchase by an insider in the last 3 months. Gary has been a buyer over the last 12 months, purchasing a net total of US$399k worth in shares.
Recent Insider Transactions • Jan 27Co-Founder & Independent Director recently bought US$61k worth of stockOn the 24th of January, Ulrik Nielsen bought around 14k shares on-market at roughly US$4.24 per share. This was the largest purchase by an insider in the last 3 months. This was Ulrik's only on-market trade for the last 12 months.
분석 기사 • May 19We're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To GrowEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Recent Insider Transactions • Mar 27President recently bought US$55k worth of stockOn the 24th of March, Gary Crocker bought around 9k shares on-market at roughly US$6.39 per share. This was the largest purchase by an insider in the last 3 months. Gary has been a buyer over the last 12 months, purchasing a net total of US$202k worth in shares.
Is New 90 Day High Low • Mar 05New 90-day low: US$6.44The company is down 9.0% from its price of US$7.07 on 04 December 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.
분석 기사 • Feb 22Are Insiders Selling Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Stock?We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...
Is New 90 Day High Low • Feb 11New 90-day high: US$8.70The company is up 135% from its price of US$3.71 on 12 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period.
분석 기사 • Jan 01Merrimack Pharmaceuticals (NASDAQ:MACK) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, Merrimack...
Is New 90 Day High Low • Nov 13New 90-day low: US$3.71The company is down 14% from its price of US$4.30 on 14 August 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period.
공시 • Jul 04Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from Russell Microcap Value IndexMerrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from Russell Microcap Value Index